SGS Implements Veeva Vault Management System Globally
SGS, a life sciences, clinical, and bioanalytical contract solutions provider, announced that the company will implement the Veeva Vault CTMS (clinical trial management system) across its network of clinical operations sites for the management of its global clinical study services. Vault CTMS will enable SGS to share reporting capabilities with its clients and deliver greater flexibility in running studies. Together with Veeva Vault eTMF (electronic trial master file.) SGS will begin running studies on Vault CTMS in spring 2019, with any current studies scheduled to end after June 2019 being migrated the new system.
"Veeva Vault CTMS, along with Veeva Vault eTMF will allow us to streamline our clinical trial management and improve decision-making within our planning and operations teams across the Americas and Europe," commented Janelle Johnson, SGS International Project Mangement Director. "SGS is committed to investing where necessary to maintain its leadership position in clinical research, and ensuring it has the most efficient systems, and in-turn, offer the highest level of service and experience to our clients."
"Veeva Vault CTMS will enable SGS' to improve its operational efficiency and drive faster, higher-quality trial execution," added Henry Galio- Senior Director, Veeva Vault CTMS. Now clinicans and managers can have greater oversight and improved decision-making capabilities during studies."
SGS Life Sciences provides clinical research, bioanalytical, biologics characterization, biosafety, and quality control testing. Delivering solutions in Europe and the US, SGS offers clinical trial (phase I and IV) services encompassing clinical project management and monitoring, biometrics, PK/PD modeling and simulation, and regulatory and medical affairs consultancy. SGS has its own clinical unit in Belgium and two phase I patient units based in Belgium and Hungary. SGS has a wealth of expertise in first in human (FIH) studies, human challenge testing, manufacturing challenge agents, biosimilars, and complex PK/KD studies with a focus on infectious diseases, vaccines, and respiratory therapeutics.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
